NeuroPace, Inc. (NASDAQ:NPCE – Get Rating) has been assigned a consensus rating of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $16.50.
A number of analysts recently weighed in on NPCE shares. Zacks Investment Research cut shares of NeuroPace from a “hold” rating to a “strong sell” rating in a research note on Wednesday, March 16th. Wells Fargo & Company decreased their price target on shares of NeuroPace from $11.00 to $9.00 and set an “equal weight” rating for the company in a research note on Friday, March 11th. Wolfe Research started coverage on shares of NeuroPace in a research note on Tuesday, April 5th. They set an “outperform” rating and a $13.00 price target for the company. Morgan Stanley cut shares of NeuroPace from an “equal weight” rating to an “underweight” rating and decreased their price target for the stock from $17.00 to $12.00 in a research note on Friday, January 7th. Finally, SVB Leerink decreased their price target on shares of NeuroPace from $15.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, March 11th.
Several hedge funds have recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of NeuroPace in the 4th quarter worth $585,000. BlackRock Inc. lifted its stake in shares of NeuroPace by 1.8% in the fourth quarter. BlackRock Inc. now owns 340,087 shares of the company’s stock valued at $3,428,000 after purchasing an additional 6,113 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of NeuroPace in the fourth quarter valued at about $1,373,000. Revelation Capital Management LLC acquired a new stake in shares of NeuroPace in the fourth quarter valued at about $6,719,000. Finally, Soleus Capital Management L.P. lifted its stake in shares of NeuroPace by 38.3% in the fourth quarter. Soleus Capital Management L.P. now owns 2,309,003 shares of the company’s stock valued at $23,275,000 after purchasing an additional 638,867 shares during the period. Institutional investors own 49.85% of the company’s stock.
NeuroPace (NASDAQ:NPCE – Get Rating) last posted its earnings results on Thursday, March 10th. The company reported ($0.44) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.11). The company had revenue of $11.00 million during the quarter, compared to analysts’ expectations of $11.00 million. NeuroPace had a negative net margin of 79.85% and a negative return on equity of 141.26%. As a group, sell-side analysts forecast that NeuroPace will post -1.96 earnings per share for the current year.
NeuroPace Company Profile (Get Rating)
NeuroPace, Inc operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
- Get a free copy of the StockNews.com research report on NeuroPace (NPCE)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.